Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatory responses. Allakos was founded in 2012 and is headquartered in San Carlos, California.

Allakos is dedicated to developing innovative therapies that target immune-mediated diseases and cancer, with a primary focus on improving the lives of patients suffering from severe conditions. Their core mission revolves around the discovery and development of novel antibody-based treatments, aiming to address unmet medical needs and provide effective solutions. By leveraging their expertise in antibody engineering and immunology, Allakos strives to make a significant impact on the healthcare landscape and transform the way patients receive treatment for complex diseases.

• Innovation: Allakos is dedicated to pushing the boundaries of science and medicine, fostering a culture of innovation that encourages employees to think outside the box and pursue groundbreaking solutions.
• Collaboration: Teamwork is essential to Allakos's success, with a collaborative environment that values open communication, mutual respect, and shared problem-solving.
• Patient focus: Allakos is committed to improving the lives of patients, with a focus on developing therapies that address unmet medical needs and provide meaningful benefits to those in need.
• Integrity: Allakos operates with the highest standards of integrity, emphasizing honesty, transparency, and ethical behavior in all aspects of its operations.